로딩 중…
지수 로딩 중…
Optipharm.CO.,LTD
153710· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,240-0.12%
2026-11-02
Financials
Valuation Metrics
Optipharm.CO.,LTD's Market Cap is ₩622B. At end of 2025 it was ₩748B. Ranked #1555 of 2,410 in KR market (top 65%), #907 of 1,631 on KOSDAQ (top 56%), #172 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 62.20B KRW | KR#1,555/2,410 Sec#172/231 |
| Revenue | 23.59B KRW | KR#2,101/2,410 Sec#151/231 |
| Net Income | -1.86B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 40.77B KRW | KR#2,271/2,410 Sec#208/231 |
| Net Assets | 25.40B KRW | KR#2,215/2,410 Sec#203/231 |
| Employees | 77 | KR#1,822/2,410 Sec#155/231 |
| Value | ||
| P/B | 2.45x | KR#2,076/2,410 Sec#161/231 |
| P/S | 2.64x | KR#1,971/2,410 Sec#117/231 |
| FCF Yield | -6.53% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -7.33% | KR#1,871/2,410 Sec#136/231 |
| ROA | -4.57% | KR#1,912/2,410 Sec#137/231 |
| Op. Margin | -7.53% | KR#1,927/2,410 Sec#129/231 |
| Revenue Growth | 11.84% | KR#809/2,410 Sec#81/231 |
| Financial Health | ||
| Debt Ratio | 60.51% | KR#1,099/2,410 Sec#131/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -4.06B KRW | KR#1,451/2,410 Sec#115/231 |
| Cash | 2.28B KRW | KR#2,219/2,410 Sec#212/231 |
| Current Ratio | 1.16x | KR#1,534/2,410 Sec#158/231 |
| Performance | ||
| 1Y Return | -15.71% | KR#1,049/2,410 Sec#69/231 |
| 1M Return | -5.78% | KR#940/2,410 Sec#94/231 |
| From 52W High | -32.16% | KR#464/2,410 Sec#31/231 |
| 1Y MDD | -31.61% | KR#305/2,410 Sec#20/231 |
| Trading | ||
| Volume | 5,505 shares | KR#2,051/2,410 Sec#208/231 |
| Trading Value | 23.2M KRW | KR#1,991/2,410 Sec#210/231 |
| Foreign Own. | 0.83% | KR#2,083/2,410 Sec#204/231 |
| Per Share | ||
| EPS | -127 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,731 KRW | KR#2,138/2,410 Sec#179/231 |
Company Info
OptiPharm, established in 2000 and listed on KOSDAQ in 2018, specializes in animal-related businesses, including disease diagnosis, pharmaceuticals, and bacteriophage. Since 2006, it has developed an independent disease appraisal system and diagnostic products. Leveraging original technologies like transgenic technology and animal-related infrastructure, the company is expanding into human-related ventures such as bacteriophage-based disease treatments and xenotransplantation development.